Business Context and Reporting Period
Lisata Therapeutics, Inc. (LSTA) filed a Form 8-K Current Report on July 15, 2025. The Company is a Delaware corporation with its principal executive offices in Basking Ridge, NJ, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the issuance of a new patent by the United States Patent and Trademark Office (USPTO). This expands the Company's intellectual property estate regarding its lead asset, certepetide.
Outlook, Risks, and Unusual Items
- Patent Grant: U.S. Patent No. 12,351,653 was issued on July 8, 2025, covering the composition of matter of certepetide, specifically its chemical structure and pharmacokinetic properties.
- Patent Expiration: The granted patent is set to expire in March 2040.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) and the patent certificate (Exhibit 99.2) by reference but does not include additional management commentary or risk factors within the body of this specific 8-K.
Investor Verification Checklist
- Verify the scope of claims in U.S. Patent No. 12,351,653 via the attached Exhibit 99.2.
- Review the full press release (Exhibit 99.1) for details on the strategic impact of the patent grant.
- Confirm the patent expiration date of March 2040 against the USPTO database.
- Check recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial data.